Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: Effect of conditioning regimen on outcome

Richard K Burt*, Xiaoqiang Han, Paula Gozdziak, Kim Yaung, Amy Morgan, Allison M. Clendenan, Jacquelyn Henry, Michelle A. Calvario, Syamal Kumar Datta, Irene Helenowski, James Schroeder

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Some patients with systemic lupus erythematosus (SLE) are refractory to traditional therapies, dependent on chronic corticosteroids, have organ damage, and are at high risk of mortality. In this group of patients, we report outcome at a median of five years after autologous hematopoietic stem cell transplant (HSCT) using two different non-myeloablative regimens. Four patients received a conditioning regimen of cyclophosphamide (200 mg/kg) and alemtuzumab (60 mg), while 26 patients underwent conditioning with cyclophosphamide (200 mg/kg), rATG (Thymoglobulin) (5.5 mg/kg), and rituximab 1000 mg. Unselected peripheral blood stem cells were infused on day 0. There were no treatment related deaths. Of the four patients treated with cyclophosphamide and alemtuzumab, none entered remission. For the 26 patients treated with cyclophosphamide, rATG, and rituximab, disease remission defined as no immune suppressive drugs except hydroxychloroquine and/or 10 mg or less of prednisone a day was 92% at 6 months, 92% at one year, 81% at 2 years, 71% at 3 years, and 62% at 4 and 5 years post-HSCT. Autologous HSCT outcome is dependent on the conditioning regimen but prior organ damage may cause lingering symptoms.

Original languageEnglish (US)
Pages (from-to)692-700
Number of pages9
JournalBone Marrow Transplantation
Volume53
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Peripheral Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Systemic Lupus Erythematosus
Adrenal Cortex Hormones
Cyclophosphamide
Hematopoietic Stem Cells
Transplants
Hydroxychloroquine
Prednisone
Mortality
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Burt, Richard K ; Han, Xiaoqiang ; Gozdziak, Paula ; Yaung, Kim ; Morgan, Amy ; Clendenan, Allison M. ; Henry, Jacquelyn ; Calvario, Michelle A. ; Datta, Syamal Kumar ; Helenowski, Irene ; Schroeder, James. / Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus : Effect of conditioning regimen on outcome. In: Bone Marrow Transplantation. 2018 ; Vol. 53, No. 6. pp. 692-700.
@article{49c24396566449d48963607005c72d35,
title = "Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: Effect of conditioning regimen on outcome",
abstract = "Some patients with systemic lupus erythematosus (SLE) are refractory to traditional therapies, dependent on chronic corticosteroids, have organ damage, and are at high risk of mortality. In this group of patients, we report outcome at a median of five years after autologous hematopoietic stem cell transplant (HSCT) using two different non-myeloablative regimens. Four patients received a conditioning regimen of cyclophosphamide (200 mg/kg) and alemtuzumab (60 mg), while 26 patients underwent conditioning with cyclophosphamide (200 mg/kg), rATG (Thymoglobulin) (5.5 mg/kg), and rituximab 1000 mg. Unselected peripheral blood stem cells were infused on day 0. There were no treatment related deaths. Of the four patients treated with cyclophosphamide and alemtuzumab, none entered remission. For the 26 patients treated with cyclophosphamide, rATG, and rituximab, disease remission defined as no immune suppressive drugs except hydroxychloroquine and/or 10 mg or less of prednisone a day was 92{\%} at 6 months, 92{\%} at one year, 81{\%} at 2 years, 71{\%} at 3 years, and 62{\%} at 4 and 5 years post-HSCT. Autologous HSCT outcome is dependent on the conditioning regimen but prior organ damage may cause lingering symptoms.",
author = "Burt, {Richard K} and Xiaoqiang Han and Paula Gozdziak and Kim Yaung and Amy Morgan and Clendenan, {Allison M.} and Jacquelyn Henry and Calvario, {Michelle A.} and Datta, {Syamal Kumar} and Irene Helenowski and James Schroeder",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/s41409-018-0173-x",
language = "English (US)",
volume = "53",
pages = "692--700",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus : Effect of conditioning regimen on outcome. / Burt, Richard K; Han, Xiaoqiang; Gozdziak, Paula; Yaung, Kim; Morgan, Amy; Clendenan, Allison M.; Henry, Jacquelyn; Calvario, Michelle A.; Datta, Syamal Kumar; Helenowski, Irene; Schroeder, James.

In: Bone Marrow Transplantation, Vol. 53, No. 6, 01.06.2018, p. 692-700.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus

T2 - Effect of conditioning regimen on outcome

AU - Burt, Richard K

AU - Han, Xiaoqiang

AU - Gozdziak, Paula

AU - Yaung, Kim

AU - Morgan, Amy

AU - Clendenan, Allison M.

AU - Henry, Jacquelyn

AU - Calvario, Michelle A.

AU - Datta, Syamal Kumar

AU - Helenowski, Irene

AU - Schroeder, James

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Some patients with systemic lupus erythematosus (SLE) are refractory to traditional therapies, dependent on chronic corticosteroids, have organ damage, and are at high risk of mortality. In this group of patients, we report outcome at a median of five years after autologous hematopoietic stem cell transplant (HSCT) using two different non-myeloablative regimens. Four patients received a conditioning regimen of cyclophosphamide (200 mg/kg) and alemtuzumab (60 mg), while 26 patients underwent conditioning with cyclophosphamide (200 mg/kg), rATG (Thymoglobulin) (5.5 mg/kg), and rituximab 1000 mg. Unselected peripheral blood stem cells were infused on day 0. There were no treatment related deaths. Of the four patients treated with cyclophosphamide and alemtuzumab, none entered remission. For the 26 patients treated with cyclophosphamide, rATG, and rituximab, disease remission defined as no immune suppressive drugs except hydroxychloroquine and/or 10 mg or less of prednisone a day was 92% at 6 months, 92% at one year, 81% at 2 years, 71% at 3 years, and 62% at 4 and 5 years post-HSCT. Autologous HSCT outcome is dependent on the conditioning regimen but prior organ damage may cause lingering symptoms.

AB - Some patients with systemic lupus erythematosus (SLE) are refractory to traditional therapies, dependent on chronic corticosteroids, have organ damage, and are at high risk of mortality. In this group of patients, we report outcome at a median of five years after autologous hematopoietic stem cell transplant (HSCT) using two different non-myeloablative regimens. Four patients received a conditioning regimen of cyclophosphamide (200 mg/kg) and alemtuzumab (60 mg), while 26 patients underwent conditioning with cyclophosphamide (200 mg/kg), rATG (Thymoglobulin) (5.5 mg/kg), and rituximab 1000 mg. Unselected peripheral blood stem cells were infused on day 0. There were no treatment related deaths. Of the four patients treated with cyclophosphamide and alemtuzumab, none entered remission. For the 26 patients treated with cyclophosphamide, rATG, and rituximab, disease remission defined as no immune suppressive drugs except hydroxychloroquine and/or 10 mg or less of prednisone a day was 92% at 6 months, 92% at one year, 81% at 2 years, 71% at 3 years, and 62% at 4 and 5 years post-HSCT. Autologous HSCT outcome is dependent on the conditioning regimen but prior organ damage may cause lingering symptoms.

UR - http://www.scopus.com/inward/record.url?scp=85047938841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047938841&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0173-x

DO - 10.1038/s41409-018-0173-x

M3 - Article

C2 - 29855561

AN - SCOPUS:85047938841

VL - 53

SP - 692

EP - 700

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -